Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety and Tolerability of Repeat-Dose Cabotegravir Long-Acting Injection in Healthy Adults
NCT04484337Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Jul 2020
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of cabotegravir in human immunodeficiency virus infection (HIV) (15 arms), sponsored by ViiV Healthcare. Primary endpoints: Time of Maximum Observed Plasma Concentration, Apparent Terminal Phase Half-life and 4 more. Started Jul 2020; status: completed.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04484337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04484337.